Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,582.92 -783.18 (-1.15%) CMC Crypto 200
1,419.10 -9.46 (-0.66%)
Tarsus Pharmaceuticals, Inc. (TARS)
After hours:
| Previous close | 34.74 |
| Open | 35.06 |
| Bid | 32.89 x 200 |
| Ask | 33.26 x 100 |
| Day's range | 31.59 - 35.69 |
| 52-week range | 12.57 - 42.50 |
| Volume | |
| Avg. volume | 591,169 |
| Market cap | 1.245B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences: William Blair Growth Stock Conference Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat on Tuesday, June 4, 2024, at 1:20 p
- GlobeNewswire
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the 2024 Bank of America Healthcare Conference taking place in Las Vegas, NV, on Wednesday, May 15, at 1:55 p.m. PT / 4
- GlobeNewswire
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025 Expanded sales force on-track to be in the field by the end of the third quarter 2024 Strengthened financial position with an approximately $108 million public equity offering and $200 million fi
